Dr. Kannan Natarajan is Head of Global Biometrics and Data Management and is part of Global Product Development Leadership Team at Pfizer Inc. The GBDM organization supports the global clinical development strategy and data sciences across all of Pfizer product portfolio. He is also the Chief Statistical Officer of Pfizer, managing statistical functional excellence across all Pfizer business units. Prior to joining Pfizer, Kannan was Senior Vice President and Global Head of Oncology Biometrics and Data Management at Novartis Pharmaceuticals. Kannan has been in the pharmaceutical industry for over 20 years working across various therapeutic areas. Kannan holds a PhD. Degree in Statistics from the University of Florida.
- Amy P. Abernethy, US FDA
- Graeme Archer, GSK R&D
- Jesse Berlin, Johnson & Johnson
- Lawrence Carin, Duke
- Noémie Elhadad, Columbia
- Igor Jurisica, Krembil Research Institute and University of Toronto
- Faisal Khan, AstraZeneca
- Kannan Natarajan, Pfizer
- Amol Navathe, University of Pennsylvania
- Adler Perotte, Columbia
- Patrick Ryan, Janssen Research and Development
- Mary Ann Slack, US Food and Drug Administration (FDA)
- Simon Tavaré, Columbia
- Mihaela van der Schaar, Cambridge
- Li Wang, AbbVie
Countdown to AIPM
AIPM has begun!
Welcome Address — David Madigan, Ph.D., Columbia University
A Perspective on the Promise and Pitfalls of Artificial Intelligence in Clinical Drug Development — Kannan Natarajan, Pfizer Inc.
Machine Learning: Changing the future of healthcare – from next generation clinical trials to individualized treatment effects — Mihaela van der Schaar, University of Cambridge
Discussant — Patrick Ryan, Janssen Research and Development
ML and AI in Clinical Development and Statistical Innovation — Wang Li, AbbVie.
Opportunities for AI in Healthcare — Lawrence Carin, Duke University
- Demissie Alemayehu, Pfizer Inc.
- David Madigan, Columbia University